Qi Liu

Qi Liu, MD, PhD, brings over 20 years of global oncology clinical development experience in both academia and industry designing and conducting phase I to Phase III clinical studies, as well as business development experience evaluating oncology assets across different development stages. She has extensive knowledge of both small molecules, biologics and immunotherapies, and genuine passion for drug development.

Currently, Dr. Liu is the advisor for a number of biotech companies focusing on innovative oncology drug development in the area of immunotherapy, bi-specific antibody, ADC, targeted therapy, radiopharmaceuticals and nanoparticle delivery platform. She guides the companies for their development strategy, product differentiation, partnering, IND, NDA, orphan drug status and break through designation applications and effective delivery. Previously, Dr. Liu was the CMO for Elucida Oncology, helped with Elucida C-dots development strategy in a variety of areas including cancer diagnostics, theranotics, nanoparticle drug conjugates, and to execute IND readiness for the therapeutics. Prior to Elucida Oncology, Dr. Liu was the CMO oncology for Zai Lab, where she was responsible for building Zai Lab’s oncology portfolio and the clinical team, leading clinical development and regulatory strategy, rapidly advancing the clinical programs, and providing overall medical and safety oversight for Zai Lab’s clinical studies. In addition, she was one of the core members taking Zai Lab IPO at NASDAQ in 2017. Prior to joining Zai Lab, Dr. Liu was the clinical head of BioVenture group at AstraZeneca and executive medical director for AstraZeneca oncology global development. She played essential roles in establishing two joint ventures for biologics development and was responsible for building and advancing joint ventures’ global clinical development programs, regulatory strategy and submissions. Dr. Liu was also the key lead for AstraZeneca’s VEGF TKI global clinical development program leading studies from phase I through phase III in multiple tumor indications, and the clinical lead of AstraZeneca oncology business development providing evaluation of all stage licensing opportunities from preclinical to M&A which led to a number of oncology licensing deals. Before joining pharma industry, Dr. Liu was an assistant professor with tenure track at MD Anderson Cancer Center.